caa a22 4500 465790011 CHVBK 20180323112021.0 cr unu---uuuuu 170327e19900501xx s 000 0 eng 10.1007/BF00177257 doi (NATIONALLICENCE)springer-10.1007/BF00177257 Phase II study of N-methylformamide (N-MF) (NSC 3051) in patients with advanced epithelial ovarian cancer [Elektronische Daten] A Gynecologic Oncology Group study [William McGuire III, John Blessing, Jonathan Berek, Alan Munoz] Summary: Forty-four patients with advanced, measurable, epithelial carcinoma of the ovary were treated with 97 courses of N-methylformamide (N-MF) at doses ranging from 600-800 mg/m2, intravenously, daily for 5 days every 28 days. Forty-one patients had prior surgery and had received one prior chemotherapy regimen. Only seven patients had received any prior radiation therapy. All patients were Gynecologic Oncology Group (GOG) performance status 0, 1, or 2. Three partial responses were seen. Hematologic adverse effects were extremely rare as predicted by early clinical trials. One major toxicity was a syndrome consisting of some combination of myalgias, arthralgias, pleuritic pain, abdominal pain, peripheral neuropathy, anorexia, lethargy, and declining performance status (painlethargy syndrome) that was reversible with discontinuation of the drug. This adverse effect was as common a reason as hepatic toxicity for discontinuation of N-MF. As reported in previous studies with this drug, hepatic toxicity was also common, usually reversible, and also a cause for discontinuation of the drug. The low level of clinical activity and the unpleasant adverse effects in this population of patients with previously treated ovarian cancer makes it unlikely that this drug will play any significant role in treatment of epithelial ovarian cancer. Kluwer Academic Publishers, 1990 N-MF nationallicence N-methylformamide nationallicence ovarian neoplasms nationallicence McGuire III William Johns Hopkins Oncology Center, Baltimore, MD, USA aut Blessing John Gynecologic Oncology Group, Cancer Research Scientist VI, Roswell Park Memorial Institute, Buffalo, NY, USA aut Berek Jonathan Division of Gynecologic Oncology, USA aut Munoz Alan Obstetrics and Gynecology University of California at Los Angeles School of Medicine and Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA aut Investigational New Drugs Kluwer Academic Publishers 8/2(1990-05-01), 191-194 0167-6997 8:2<191 1990 8 10637 https://doi.org/10.1007/BF00177257 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00177257 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- McGuire III William Johns Hopkins Oncology Center, Baltimore, MD, USA aut NATIONALLICENCE 700 1- Blessing John Gynecologic Oncology Group, Cancer Research Scientist VI, Roswell Park Memorial Institute, Buffalo, NY, USA aut NATIONALLICENCE 700 1- Berek Jonathan Division of Gynecologic Oncology, USA aut NATIONALLICENCE 700 1- Munoz Alan Obstetrics and Gynecology University of California at Los Angeles School of Medicine and Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/2(1990-05-01), 191-194 0167-6997 8:2<191 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence SWISSBIB 465790011 BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer